Study shows longer treatment for children with langerhans cell hystiocytosis improves survival rates

May 29, 2013, Children's National Medical Center

A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis (MS-LCH) can achieve survival rates as high as 84 percent—a full 15 percent improvement over the previous clinical trial in this series.

The study, LCH-III, is published in Blood, the journal of the American Society of . It is the third in a series of international for LCH that spans twenty years initiated and coordinated by the Histiocyte Society, a group of more than 200 physicians and scientists worldwide. The LCH clinical trial series are the first randomized for the of LCH.

Langerhans cells are found throughout the body and help regulate the . In LCH, the cells proliferate excessively in a single organ or in multiple , damaging surrounding tissue and producing a wide range of symptoms. LCH occurs most often in children and its cause is unknown. In the most serious cases, LCH affects "risk organs," such as the liver or lungs, and can be fatal.

In this study, high-risk patients received one or two six-week courses of , followed by milder continuation therapy in those who responded to the initial course—for a combined 12 months of treatment. The overall five-year survival probability for these patients was 84 percent—substantially higher than in the two preceding trials (62 percent for LCH-I and 69 percent for LCH-II), in which patients were treated for six months. Moreover, the five-year risk of disease reactivation was much lower (27 percent) than in comparable patients in the two earlier trials.

Lower-risk patients in this study who responded after an initial six-week course of treatment were randomly assigned to receive six or 12 months' total treatment. The longer 12-month treatment significantly decreased the disease reactivation rate (37 percent), compared to the six-month treatment group (54 percent).

The study authors note that the first 12 weeks of treatment seem to be a critical time for patient outcomes with MS-LCH and that "aggressive salvage therapy was quite effective in patients not responding to the protocol therapy"—achieving a survival rate of 75 percent.

"These findings are real cause for hope for children with multi-system LCH, now that we have achieved improved in these three sequential studies," said senior author Stephan Ladisch, MD, a researcher in the Center for Cancer and Immunology Research at the Children's Research Institute and Professor of Pediatrics and Biochemistry/Molecular Biology at Children's National Medical Center. "The international collaboration in these trials has been essential to making significant progress against such a rare disorder, and children around the world will benefit from this research."

Results of the first LCH clinical trial were published in 2001 in the Journal of Pediatrics. Findings from the second trial were published in Blood in 2008. Goals for future trials include reduction of the remaining 15 percent mortality among with risk-organ involvement and reduction of the 30-40 percent disease reactivation rate.

Explore further: Study finds one treatment stands above others for adults with Langerhans cell histiocytosis

Related Stories

Study finds one treatment stands above others for adults with Langerhans cell histiocytosis

August 15, 2012
A study by a Baylor College of Medicine physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis (LCH) in bones. LCH is a disease that can affect the skin, mouth, ears, ...

Experimental drug beneficial in NIH trial to treat a rare sarcoma

May 7, 2013
(Medical Xpress)—Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib. The results from this largest clinical ...

New protein-targeting drug shows promise in early trial for patients with high-risk CLL

May 17, 2013
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...

Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity

May 23, 2013
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...

The value of randomized clinical trials in radiation oncology clinical practice

May 29, 2013
Cancer patients, physicians and insurers want to be sure that whatever therapy is recommended and provided to patients is based on evidence, preferably results from randomized clinical trials. But are there enough clinical ...

Intensified chemotherapy shows promise for children with very high risk form of leukemia

December 10, 2012
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.